☆ 4.3 Letter

Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7+3) in newly diagnosed high-risk acute myeloid leukemia (AML)

LEUKEMIA RESEARCH (2018)

Get Full Text
Add to Collection

Journal

LEUKEMIA RESEARCH
Volume 72, Issue -, Pages 92-95

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2018.08.005

Keywords

-

Categories

Oncology Hematology

Funding

  1. NCI [U01 CA70095]
  2. NCI Cancer Center Support Grant [2P30 CA06973-46]
  3. NATIONAL CANCER INSTITUTE [U10CA180838, P30CA016672, P30CA006973] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.